GB-Policy&Regulation (Premium-1): Lead Exposure Is Still a Problem for Kids, and the Pandemic Has Made It Worse
Lead exposure continues to threaten the health and development of children across the country, despite longstanding efforts to eliminate this toxic hazard from homes, schools, and communities. The COVID-19 pandemic has exacerbated the problem, as lockdowns and school closures have increased children’s time in potentially hazardous environments and disrupted routine lead screenings and prevention programs. Many families, especially those in underserved areas, now face greater challenges in accessing resources and support. As a result, the risk of lead poisoning and its lifelong consequences has grown, underscoring the urgent need for renewed public health attention and intervention.
• By Nabil, John Cena, James Milner, Elizabeth, Alexander, and Christopher Theodore
Generate a summary of this article
Listen to this article
Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.
India Has Multiple COVID-19 Vaccines For Children. How Are They Faring? • Source: Shutterstock
The good news – if it’s possible to describe a slow, insidious, and permanent poisoning as “good news” – is that the blood lead levels of children in the United States have dropped steadily over the past half-century.
Quick Facts
Lead is a toxic metal that can harm children’s brain development, even at low levels of exposure.
Stay ahead of every shift in generics and biosimilars.
Generics Bulletin brings you the latest updates that matter for the off-patent industry.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Following on from its recently announced US licensing deal with Amneal over its Xolair biosimilar, Kashiv has finished patient recruitment for a trial for the omalizumab candidate, paving the way for submissions.
• By Nabil, John Cena, James Milner, Elizabeth, Alexander, and Christopher Theodore
Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.